Crestor is a drug owned by Ipr, containing the active ingredient rosuvastatin calcium. It was first authorised for market use on 12 August, 2003. This drug is available in tablet;oral dosage forms.
The Crestor generic will be possible to be released after 27 May, 2023. This is because, although Crestor has a total of 1 drug patent, the last patent (US6858618*PED) is due to expire on 2022-06-17. Therefore, the earliest possible date for the release of Crestor generic is after the patent expiration.
The active ingredient in Crestor, rosuvastatin calcium, is used in the treatment of heterozygous familial hypercholesterolemia.
Crestor has a sole drug patent (US6858618*PED) that is due to expire on 17 June, 2022. Below is the details of the patent.